9 hrs ago
DePuy Pinnacle Lawsuit Update: Federal Court Orders DePuy to Produce...
The firm is actively filing DePuy Pinnacle lawsuits on behalf of individuals who allegedly suffered metallosis, premature device failure and other serious complications related to the metal-on-metal hip implant.
15 hrs ago
Drug Store News
J&J plans slew of regulatory filings through 2017
Johnson & Johnson expects to file for Food and Drug Administration approval of more than 10 new drugs over the next four years, the drug maker said Thursday.
Thu May 23, 2013
J&J expects 10-plus new drug applications by 2017
Johnson & Johnson is developing what could eventually be game-changing treatments for depression and pain, and it's aiming to apply for approval of more than 10 new medicines by 2017, executives said Thursday during a review of the health care giant's medicine business.
J&J hopes for 10 new treatments by 2017
Health-care giant Johnson & Johnson plans to seek approval for 10 new treatments to combat cancer, Hepatitis C, schizophrenia and influenza over the next four years, the company said Thursday.
Johnson & Johnson Coverage Initiated at Credit Suisse
The firm set an "underperform" rating on the stock. A number of other firms have also recently commented on JNJ.
J&J forecasts 10 new drug applications by 2017
Johnson & Johnson says it plans to submit more than 10 new treatments to regulators for approval and 25 applications for additional uses of approved drugs by 2017.
Wed May 22, 2013
Johnson & Johnson Asks Employees to Assess Its Battered Corporate Credo
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today! In the wake of scandals and investigations over manufacturing gaffes, countless product recalls and questionable marketing practices, Johnson & Johnson is embarking on a round of corporate soul searching.
Tue May 21, 2013
DePuy Announces It Will Stop Selling Metal-On-Metal Hip Implants, Notes Rottenstein Law Group LLP
The firm is actively filing DePuy ASR lawsuits on behalf of those who allegedly suffered metallosis, premature device failure, or other serious complications related to the 2010 DePuy ASR recall.
Sun May 19, 2013
The Motley Fool
Will Obamacare Crush Medtronic's Earnings?
The key to making smart investment decisions on stocks reporting earnings is to anticipate how they'll do before they announce results, leaving you fully prepared to respond quickly to whatever inevitable surprises arise.
Fri May 17, 2013
Johnson & Johnson Outlines Poppy Supply Plans
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today! Johnson and Johnson could be sourcing commercial quantities of poppies outside Tasmania in 2015.
The Washington Post
Johnson & Johnson Ending Sales of Metal-on-Metal Hip Implants
Johnson & Johnson, the world's biggest maker of health-care products, said it will stop selling metal-on-metal and ceramic-on-metal hip replacements as demand wanes for the devices and U.S. regulators seek new rules.
Wed May 15, 2013
Stryker's Stock Looks Pricey
Assessing whether a stock is a "value play" or a "value trap" has become a popular hobby for financial writers.
Mon May 13, 2013
Buffett Style Valuation Of Johnson & Johnson
In this article, I'm going to show how much Johnson & Johnson stock is worth according to a Warren Buffett "owner earnings" style analysis.
Fri May 10, 2013
Silicon Alley Insider
Video Of Half A Second Of High Frequency Trading Activity Looks Like A Battle In Star Wars
Nanex LLC founder Eric Hunsader presented on High Frequency trading at Wired's Business Conference , and he showed this powerful video of half a second of trading in Johnson & Johnson .
Will Male Breasts Derail a Johnson & Johnson Settlement Over Risperdal Marketing?
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today! A much-anticipated settlement of various federal government probes into Johnson & Johnson marketing of the Risperdal antipsychotic, as well as other medications, is being delayed over language the health care giant fears may cause difficulties for a raft of ... (more)
Thu May 09, 2013
The Beaumont Enterprise
Medical Device Companies Eke Out Growth In Tough Market, Finds Latest Kalorama Report
Medical Device Companies Eke Out Growth In Tough Market, Finds Latest Kalorama Report In the U.S. Medicare, Medicaid, as well as state governments implemented anemic spending increases to hospitals, the key buyer of medical device products.The beginning of 2013 saw the medical device industry make the first payments to the IRS for a new 2.3% ... (more)
Johnson & Johnson: Banking On Industry Revival
The pharmaceutical industry has been subject to a major patent cliff as some of the strongest products lost patent protection.
Wed May 08, 2013
Coloplast ranked as the best medtech company by patient groups
In a new global study carried out among 412 patient groups from 39 different countries Coloplast is ranked at the very top in front of large international competitors such as Johnson & Johnson and Smith & Nephew.
Sun May 05, 2013
Apple Inc. (AAPL), Johnson & Johnson (JNJ), The Procter & Gamble...
With the S&P 500 having hit new all-time record highs on Friday, it's a good time to take a look back and see where the index's most recent gains have come from.
Fri May 03, 2013
Johnson & Johnson Halts Tylenol Production in South Korea Over Mishap
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today! Johnson & Johnson may have a new image campaign to help consumers, investors and physicians overlook the cascade of recalls and scandals , but such promotional efforts are no substitute for improved manufacturing procedures.